多学科主动脉团队应用血管腔内修复术治疗马凡和Loeys-Dietz综合征安全持久
该多中心研究分析了419例马凡或Loeys-Dietz综合征患者中39例接受血管腔内主动脉修复术(EVAR)的中期结局。非安全锚定区与安全近端锚定区的再干预率无统计学显著差异(P=0.609),计划性与急诊手术的再干预概率也无显著差异(P=0.916)。结论认为,在安全锚定区患者中EVAR可行且安全,多学科主动脉团队可在自体组织锚定区实施。
要点
- 419例马凡或Loeys-Dietz综合征患者中39例(9%)接受EVAR。
- 非安全锚定区与安全近端锚定区的再干预率无统计学显著差异(P=0.609)。
- 计划性与急诊EVAR的再干预概率无显著差异(P=0.916)。
核心结论
- 在马凡和Loeys-Dietz综合征且锚定区安全的患者中,EVAR可行且安全。
- 即使锚定区位于自体组织,多学科主动脉团队采用血管腔内治疗仍是可行选择。
研究设计与样本
- 分析2个欧洲中心马凡和Loeys-Dietz综合征接受EVAR的患者数据。
- 按手术时机(计划与急诊)和锚定区性质(安全与非安全)进行分析。
- 主要终点为无再干预生存,次要终点为无卒中、出血和死亡生存。
主要发现
- 419例患者中马凡352例、Loeys-Dietz综合征67例,39例(9%)接受EVAR。
- 胸主动脉腔内修复34例,腹主动脉腔内修复5例。
- 首次胸主动脉腔内修复/EVAR平均年龄48.5±15.4岁,平均随访5.9±4.4年。
- 非安全锚定区与安全近端锚定区的再干预率无统计学显著差异(P=0.609)。
- 计划性血管腔内干预后再干预概率与急诊手术相比无显著增加(P=0.916)。
关键数值与推荐
- EVAR指征:主动脉夹层13例(33%)、主动脉瘤22例(57%)、其他4例(10%)。
- 计划性干预后再干预中位时间3.9年(95%CI 2.0-5.9年),急诊手术后2.0年(95%CI -1.1至5.1年)(P=0.23)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to report on mid-term outcomes after endovascular aortic repair (EVAR) in patients with Marfan (MFS) or Loeys-Dietz (LDS) syndrome. METHODS: We analysed data from 2 European centres of patients with MFS and LDS undergoing EVAR. Patients were analysed based on (i) timing of the procedure (planned versus emergency procedure) and (ii) the nature of the landing zone (safe versus non-safe). The primary end-point was freedom from reintervention. Secondary end-points were freedom from stroke, bleeding and death. RESULTS: A population of 419 patients with MFS (n = 352) or LDS (n = 67) was analysed for the purpose of this study. Thirty-nine patients (9%) underwent EVAR. Indications for thoracic endovascular aortic repair or EVAR were aortic dissection in 13 (33%) patients, aortic aneurysm in 22 (57%) patients and others (intercostal patch aneurysm, penetrating atherosclerotic ulcer, pseudoaneurysm, kinking of frozen elephant trunk (FET)) in 4 (10%) patients. Thoracic endovascular repair was performed in 34 patients, and abdominal endovascular aortic repair was performed in 5 patients. Mean age at 1st thoracic endovascular aortic repair/EVAR was 48.5 ± 15.4 years. Mean follow-up after 1st thoracic endovascular aortic repair/EVAR was 5.9 ± 4.4 years. There was no statistically significant difference in the rate of reinterventions between patients with non-safe landing zone and the patients with safe proximal landing zone (P = 0.609). Furthermore, there was no increased probability for reintervention after planned endovascular intervention compared to emergency procedures (P = 0.916). Mean time to reintervention, either open surgical or endovascular, after planned endovascular intervention was in median 3.9 years (95% confidence interval 2.0-5.9 years) and 2.0 years (95% confidence interval -1.1 to 5.1 years) (P = 0.23) after emergency procedures. CONCLUSIONS: EVAR in patients with MFS and LDS and a safe landing zone is feasible and safe. Endovascular treatment is a viable option when employed by a multi-disciplinary aortic team even if the landing zone is in native tissue.
引用
- Nucera M, Kreibich M, Yildiz M, et al. Endovascular aortic repair in patients with Marfan and Loeys-Dietz syndrome is safe and durable when employed by a multi-disciplinary aortic team. Eur J Cardiothorac Surg. 2024. PMID: 38430465. doi:10.1093/ejcts/ezae069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。